Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $153
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target from $151 to $153.
Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target from $151 to $153.